P L Weiden
Overview
Explore the profile of P L Weiden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
2785
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weiden P, Breitz H
Crit Rev Oncol Hematol
. 2001 Oct;
40(1):37-51.
PMID: 11578915
Pretargeted radioimmunotherapy (PRIT) was first investigated in a series of phase I and phase II studies in patients with adenocarcinoma using a pancarcinoma antibody, NR-LU-10. The principles and schema developed...
2.
Hortobagyi G, Ueno N, Xia W, Zhang S, Wolf J, Putnam J, et al.
J Clin Oncol
. 2001 Jul;
19(14):3422-33.
PMID: 11454891
Purpose: Preclinical studies have demonstrated that the adenovirus type 5 E1A gene is associated with antitumor activities by transcriptional repression of HER-2/neu and induction of apoptosis. Indeed, E1A gene therapy...
3.
Breitz H, Fisher D, Goris M, Knox S, Ratliff B, Murtha A, et al.
Cancer Biother Radiopharm
. 2000 Jun;
14(5):381-95.
PMID: 10850323
Unlabelled: Pretargeted radioimmunotherapy permits the administration of doses of 90Y five times higher than is possible with antibodies directly labeled with 90Yttrium (90Y). These high doses of 90Y introduced new...
4.
Weiden P, Breitz H, Press O, Appelbaum J, Bryan J, Gaffigan S, et al.
Cancer Biother Radiopharm
. 2000 Mar;
15(1):15-29.
PMID: 10740649
Pretargeted radioimmunotherapy (PRIT) was investigated in patients with non-Hodgkin's lymphoma (NHL). The PRIT approach used in this study is a multi-step delivery system in which an antibody is used to...
5.
Knox S, Goris M, Tempero M, Weiden P, Gentner L, Breitz H, et al.
Clin Cancer Res
. 2000 Feb;
6(2):406-14.
PMID: 10690517
A Phase II study of yttrium-90-tetra-azacyclododecanetetra-acetic acid-biotin (90Y-DOTA-biotin) pretargeted by NR-LU-10 antibody/streptavidin (SA) was performed. The primary objectives of the study were to evaluate the efficacy and safety of this...
6.
Breitz H, Weiden P, Beaumier P, Axworthy D, Seiler C, Su F, et al.
J Nucl Med
. 2000 Jan;
41(1):131-40.
PMID: 10647616
Unlabelled: Pretargeted radioimmunotherapy (PRIT) was evaluated using an antibody-streptavidin conjugate, followed by a biotin-galactose-human serum albumin clearing agent and 90Y-dodecane tetraacetic acid (DOTA)-biotin as the final step for therapy. The...
7.
Gopal A, Schuetze S, Maloney D, Weiden P
Blood
. 1999 Nov;
94(7):2537.
PMID: 10576806
No abstract available.
8.
Weiden P, Bauermeister D, Fatta E
Lancet
. 1998 Jul;
351(9109):1098.
PMID: 9660580
No abstract available.
9.
Riordan M, Weiden P
Am J Hematol
. 1998 Jun;
58(2):150-2.
PMID: 9625586
Indwelling central venous access devices are frequently associated with catheter-related thrombosis. The factor V Leiden gene mutation decreases the sensitivity of factor V to the anticoagulant activity of activated protein...
10.
Chen C, Seidel K, Armitage J, Fay J, Appelbaum F, Horowitz M, et al.
Biol Blood Marrow Transplant
. 1998 Mar;
3(6):331-40.
PMID: 9502301
Overdoses of high-dose chemotherapy before hematopoietic cell transplantation are serious adverse events, but their frequency and etiology are unknown. The American Society for Blood and Marrow Transplantation (ASBMT) conducted an...